Trexquant Investment’s Kalaris Therapeutics KLRS Stock Holding History

Trexquant Investment’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121K	Buy	+29,737	New	+$154K	﹤0.01%	1827
2023 Q1	–	Sell	-2,956	Closed	-$349K	–	1846
2022 Q4	$349K	Buy	+2,956	New	+$501K	0.01%	1051
2022 Q3	–	Sell	-660	Closed	-$59K	–	1907
2022 Q2	$59K	Buy	+660	New	+$69.2K	﹤0.01%	1462
2022 Q1	–	Sell	-1,548	Closed	-$461K	–	1802
2021 Q4	$461K	Buy	+1,548	New	+$718K	0.03%	688
2021 Q2	–	Sell	-488	Closed	-$263K	–	1570
2021 Q1	$263K	Buy	+488	New	+$410K	0.02%	818

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Trexquant Investment's KLRS Position: Q2 2026 in Review

Trexquant Investment opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 29,737 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in KLRS as recently as Q4 2022.

Trexquant Investment first reported a position in KLRS in Q1 2021 and has held it in 5 quarters since. The position peaked at $461K in Q4 2021. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

Trexquant Investment held 29,737 shares of Kalaris Therapeutics worth $121K as of Q2 2026.
Kalaris Therapeutics was a new Trexquant Investment position in Q2 2026.
Kalaris Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1827 holding.
Trexquant Investment first reported a position in Kalaris Therapeutics in Q1 2021 and has held it in 5 quarters since.
Trexquant Investment's Kalaris Therapeutics position peaked at $461K in Q4 2021.
57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.